

# Walter Fiedler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7312572/publications.pdf>

Version: 2024-02-01

202  
papers

12,068  
citations

38720

50  
h-index

28275

105  
g-index

208  
all docs

208  
docs citations

208  
times ranked

13013  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 664-671.	0.6	4
2	Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis. <i>Antibiotics</i> , 2022, 11, 128.	1.5	2
3	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	3.2	70
4	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by $\gamma\delta$ T Cells in Ovarian Cancer. <i>Cells</i> , 2022, 11, 964.	1.8	19
5	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
6	Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
7	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. <i>Blood Advances</i> , 2022, 6, 5345-5355.	2.5	24
8	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
9	Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment. <i>Cancers</i> , 2022, 14, 2773.	1.7	1
10	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. <i>Leukemia and Lymphoma</i> , 2022, 63, 2645-2651.	0.6	2
11	Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone. <i>British Journal of Haematology</i> , 2021, 192, e60-e63.	1.2	3
12	Newly diagnosed isolated myeloid sarcoma—paired NGS panel analysis of extramedullary tumor and bone marrow. <i>Annals of Hematology</i> , 2021, 100, 499-503.	0.8	9
13	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021, 100, 1181-1194.	0.8	27
14	Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. <i>Scientific Reports</i> , 2021, 11, 5803.	1.6	40
15	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021, 5, 2294-2304.	2.5	60
16	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , 2021, 106, 2986-2989.	1.7	5
17	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <i>Journal of Clinical Medicine</i> , 2021, 10, 2274.	1.0	19
18	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9

#	ARTICLE	IF	CITATIONS
19	Clonal evolution of acute myeloid leukemia with <i>FLT3</i> -ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	0.6	91
20	High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells. <i>Frontiers in Immunology</i> , 2021, 12, 675731.	2.2	15
21	Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. <i>Annals of Hematology</i> , 2021, 100, 2727-2732.	0.8	8
22	The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia. <i>Annals of Hematology</i> , 2021, 100, 2933-2941.	0.8	5
23	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	1.2	10
24	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	2.5	5
25	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2021, 11, 163.	2.8	17
26	Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10670.	1.8	6
27	Bone Marrow-Resident V $\alpha$ 1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. <i>Frontiers in Medicine</i> , 2021, 8, 763773.	1.2	21
28	Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12919.	1.8	27
29	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and <i>FLT3</i> Internal Tandem Duplications. <i>Blood</i> , 2021, 138, 692-692.	0.6	1
30	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
31	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
32	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 92.	6.9	28
33	Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. <i>Frontiers in Immunology</i> , 2020, 11, 580557.	2.2	50
34	Safety and efficacy of BAY1436032 in <i>IDH1</i> -mutant AML: phase I study results. <i>Leukemia</i> , 2020, 34, 2903-2913.	3.3	38
35	Downregulation of <i>GLI3</i> Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5084.	1.8	15
36	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73

#	ARTICLE	IF	CITATIONS
37	Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients. <i>Blood Advances</i> , 2020, 4, 5936-5941.	2.5	16
38	Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg. <i>Oncology Research and Treatment</i> , 2020, 43, 307-313.	0.8	32
39	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e169-e173.	1.2	14
40	The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 451-462.	1.5	11
41	Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis. <i>Cancers</i> , 2020, 12, 1678.	1.7	3
42	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 602.	1.8	15
43	Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. <i>Pharmacotherapy</i> , 2020, 40, 479-483.	1.2	3
44	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , 2020, 135, 2137-2145.	0.6	470
45	Transforming growth factor beta type 1 (TGF- $\beta$ 1) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells. <i>Aging</i> , 2020, 12, 23478-23496.	1.4	26
46	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). <i>Blood</i> , 2020, 136, 39-40.	0.6	6
47	Increased Frequency of TOX+ CD39+ TIGIT+ CD73- CD8+ T Cells in Patients with Newly Diagnosed AML. <i>Blood</i> , 2020, 136, 36-36.	0.6	0
48	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). <i>Blood</i> , 2020, 136, 42-42.	0.6	0
49	Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols. <i>Blood</i> , 2020, 136, 37-38.	0.6	4
50	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. <i>Blood</i> , 2020, 136, 33-35.	0.6	1
51	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Oncolmmunology</i> , 2019, 8, e1674605.	2.1	59
52	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
53	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1277-1284.	0.8	494
54	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1663.	1.7	10

#	ARTICLE	IF	CITATIONS
55	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. <i>Haematologica</i> , 2019, 104, e63-e64.	1.7	4
56	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389.	3.3	396
57	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
58	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 583-587.	1.2	5
59	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019, 185, 595-598.	1.2	19
60	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , 2018, 3, e000303.	2.0	12
61	High mobility group box 1 (HMGB1) acts as an "alarmin" to promote acute myeloid leukaemia progression. <i>Oncolimmunology</i> , 2018, 7, e1438109.	2.1	34
62	Acute hepatitis as a prequel to very severe aplastic anemia. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 51-54.	0.2	4
63	Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates. <i>Nanoscale</i> , 2018, 10, 5827-5833.	2.8	19
64	A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. <i>Oncolimmunology</i> , 2018, 7, e1450710.	2.1	111
65	Phase I study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSC17-10 CIARA trial). <i>British Journal of Haematology</i> , 2018, 183, 235-241.	1.2	2
66	Acute Myeloid Leukemia and the Bone Marrow Niche"Take a Closer Look. <i>Frontiers in Oncology</i> , 2018, 8, 444.	1.3	66
67	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018, 132, 1703-1713.	0.6	237
68	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018, 37, 5269-5280.	2.6	65
69	Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. <i>ESMO Open</i> , 2018, 3, e000381.	2.0	10
70	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia"results of the AMLSC 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
71	Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. <i>Mammalian Genome</i> , 2018, 29, 694-702.	1.0	29
72	Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression. <i>Cellular and Molecular Immunology</i> , 2018, 15, 994-997.	4.8	9

#	ARTICLE	IF	CITATIONS
73	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018, 132, 1501-1501.	0.6	3
74	Mebendazole Exerts Potent Anti-Leukemic Effects By Downregulating Protein Levels of Hedgehog Transcription Factors GLI1 and GLI2. <i>Blood</i> , 2018, 132, 5145-5145.	0.6	1
75	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 895-904.	0.8	7
76	The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. <i>EBioMedicine</i> , 2017, 22, 44-57.	2.7	167
77	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	0.8	299
78	Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 29187-29201.	0.8	28
79	Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia. <i>Translational Cancer Research</i> , 2017, 6, S286-S291.	0.4	0
80	Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone. <i>Journal of Surgical Oncology</i> , 2016, 113, 515-521.	0.8	9
81	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016, 101, 839-845.	1.7	22
82	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	0.8	61
83	A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. <i>European Journal of Cancer</i> , 2016, 63, 55-63.	1.3	57
84	Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2016, 97, 239-244.	1.1	9
85	Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2016, 4, 390-392.	0.4	7
86	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged $\geq 65$ Years with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 102-102.	0.6	40
87	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2016, 128, 1207-1207.	0.6	10
88	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 337-337.	0.6	5
89	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016, 128, 449-449.	0.6	18
90	BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles. <i>Blood</i> , 2016, 128, 592-592.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology, 2016, 34, 7007-7007.	0.8	22
92	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget, 2016, 7, 32532-32542.	0.8	75
93	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Blood, 2016, 128, 1662-1662.	0.6	0
94	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2015, 100, e122-e124.	1.7	20
95	Thrombin generation in a patient with an acquired high-titre factor V inhibitor. Blood Coagulation and Fibrinolysis, 2015, 26, 81-87.	0.5	3
96	Expression of Hedgehog Pathway Mediator <i>GLI1</i> Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical Cancer Research, 2015, 21, 2388-2398.	3.2	88
97	Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. Lung, 2015, 193, 567-570.	1.4	16
98	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations. British Journal of Haematology, 2015, 169, 694-700.	1.2	90
99	ErbB2 signaling activates the Hedgehog pathway via PI3K/Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts. Cellular Signalling, 2015, 27, 373-381.	1.7	45
100	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3A <sub>mut</sub> ) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSC). Blood, 2015, 126, 226-226.	0.6	4
101	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2586-2586.	0.6	1
102	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). Blood, 2015, 126, 322-322.	0.6	32
103	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. Blood, 2015, 126, 3789-3789.	0.6	3
104	Expression and Release of Platelet Protein Disulfide (PDI) Isomerase Is Increased in Patients with Hemophilia a. Blood, 2015, 126, 1085-1085.	0.6	0
105	New Antiangiogenic Strategies beyond Inhibition of Vascular Endothelial Growth Factor with Special Focus on Axon Guidance Molecules. Oncology, 2014, 86, 46-52.	0.9	18
106	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncology, 2014, 10, 1157-1165.	1.1	22
107	Contribution of the vascular bone marrow niche to leukemia progression. Memo - Magazine of European Medical Oncology, 2014, 7, 198-201.	0.3	1
108	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood, 2014, 124, 1426-1433.	0.6	204

#	ARTICLE	IF	CITATIONS
109	Overexpression of Gremlin-1 in Patients with Loey's-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection. <i>PLoS ONE</i> , 2014, 9, e104742.	1.1	13
110	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2014, 124, 1254-1254.	0.6	0
111	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts $\leq 10 \times 10^9/L$ . <i>Blood</i> , 2014, 124, 2636-2636.	0.6	0
112	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
113	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 315-323.	0.8	48
114	Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. <i>Molecular Cancer</i> , 2013, 12, 144.	7.9	12
115	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. <i>Blood</i> , 2013, 122, 2443-2452.	0.6	178
116	Acute Megakaryoblastic Leukemia in a Patient with Xeroderma Pigmentosum: Discussion of Pathophysiological, Prognostic, and Toxicological Aspects. <i>Acta Haematologica</i> , 2013, 129, 121-125.	0.7	6
117	Late Recurrence of a Pineal Germinoma 14 Years after Radiation and Chemotherapy: A Case Report and Review of the Literature. <i>Onkologie</i> , 2013, 36, 371-373.	1.1	3
118	Chylothorax in a Patient with Hodgkin's Lymphoma: A Case Report and Review of the Literature. <i>Tumori</i> , 2013, 99, e96-e99.	0.6	14
119	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013, 122, 2555-2555.	0.6	0
120	Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature. <i>Tumori</i> , 2013, 99, e96-9.	0.6	9
121	Critical Imbalance of TNF- $\alpha$ and Soluble TNF Receptor 1 in a Patient with Macrophage Activation Syndrome: Potential Implications for Diagnostics and Treatment. <i>Acta Haematologica</i> , 2012, 128, 69-72.	0.7	24
122	CD146: a new partner for VEGFR2. <i>Blood</i> , 2012, 120, 2164-2165.	0.6	6
123	VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 879-887.	1.7	7
124	The metabolite 3-hydroxyglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature. <i>Cancer Letters</i> , 2012, 326, 161-167.	3.2	3
125	Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment. <i>Blood</i> , 2012, 120, 411-411.	0.6	10
126	Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 433-438.	0.2	50



#	ARTICLE	IF	CITATIONS
127	Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. <i>European Journal of Radiology</i> , 2011, 80, 655-661.	1.2	6
128	Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2889-2896.	0.8	351
129	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 117, 4561-4568.	0.6	99
130	Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone. <i>Journal of Orthopaedic Research</i> , 2011, 29, 1251-1258.	1.2	15
131	Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 593-599.	0.9	45
132	Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 682-689.	0.8	53
133	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. <i>Cancer Research</i> , 2011, 71, 1362-1373.	0.4	117
134	A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). <i>Acta Oncologica</i> , 2011, 50, 121-126.	0.8	36
135	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2010, 116, 614-616.	0.6	170
136	Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 777-788.	1.9	91
137	TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. <i>Investigational New Drugs</i> , 2010, 28, 825-833.	1.2	34
138	Microcirculation of secondary bone tumors in vivo: The impact of minor surgery at a distal site. <i>Journal of Orthopaedic Research</i> , 2010, 28, 1515-1521.	1.2	13
139	An open-label, Phase I study of cediranib (RECENTIN <sup>®</sup> ) in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 196-202.	0.4	40
140	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. <i>Histopathology</i> , 2010, 57, 418-426.	1.6	30
141	TGF- $\beta$ Superfamily Receptors: Targets for Antiangiogenic Therapy?. <i>Journal of Oncology</i> , 2010, 2010, 1-10.	0.6	15
142	Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041). <i>Clinical Cancer Research</i> , 2010, 16, 1315-1323.	3.2	39
143	Isolated Limb Perfusion with Melphalan for the Treatment of Intractable Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. <i>Acta Haematologica</i> , 2010, 123, 179-181.	0.7	16
144	Single Nucleotide Polymorphism in the Mutational Hotspot of <i>WT1</i> Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 578-585.	0.8	119

#	ARTICLE	IF	CITATIONS
145	FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease's course?. Turkish Journal of Haematology, 2010, 27, 133-134.	0.2	1
146	Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology, 2010, 28, 2356-2364.	0.8	229
147	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology, 2010, 41, 1577-1585.	1.1	79
148	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 551-558.	0.6	16
149	Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2009, 27, 6152-6159.	0.8	96
150	PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leukemia Research, 2008, 32, 1857-1865.	0.4	18
151	Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. British Journal of Haematology, 2008, 142, 115-118.	1.2	21
152	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. Journal of Experimental and Clinical Cancer Research, 2008, 27, 86.	3.5	89
153	Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood, 2008, 111, 4355-4364.	0.6	163
154	Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis. Clinical Cancer Research, 2007, 13, 76-80.	3.2	44
155	Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. Oncology Research and Treatment, 2007, 30, 519-524.	0.8	24
156	CFU-EC: how they were originally defined. Blood, 2007, 110, 1073-1073.	0.6	12
157	Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochemical and Biophysical Research Communications, 2007, 357, 1016-1020.	1.0	31
158	An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 895-895.	0.6	0
159	Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leukemia and Lymphoma, 2006, 47, 2601-2609.	0.6	25
160	Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leukemia and Lymphoma, 2006, 47, 1387-1391.	0.6	10
161	Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains. Nature Methods, 2006, 3, 737-744.	9.0	31
162	Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 433-433.	0.6	6

#	ARTICLE	IF	CITATIONS
163	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. Blood, 2006, 108, 1949-1949.	0.6	1
164	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. Blood, 2006, 108, 3947-3947.	0.6	0
165	Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients ≥60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 607-607.	0.6	0
166	Cilengitide Inhibits Proliferation and Differentiation of Human Endothelial Progenitor Cells In Vitro.. Blood, 2006, 108, 3929-3929.	0.6	0
167	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105, 986-993.	0.6	481
168	Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood, 2005, 106, 3958-3961.	0.6	79
169	Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival. Journal of Clinical Oncology, 2005, 23, 1109-1117.	0.8	97
170	Difficult Diagnostic Cases. Journal of Clinical Oncology, 2005, 23, 3624-3626.	0.8	23
171	Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. European Journal of Cancer, 2005, 41, 1073-1085.	1.3	17
172	Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2005, 50, 51-58.	0.9	38
173	Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.. Blood, 2005, 106, 172-172.	0.6	17
174	Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≥60 Years with Standard Risk AML.. Blood, 2005, 106, 151-151.	0.6	0
175	An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thrombosis and Haemostasis, 2004, 92, 1136-1146.	1.8	25
176	Identification of the Adult Human Hemangioblast. Stem Cells and Development, 2004, 13, 229-242.	1.1	77
177	Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Experimental Cell Research, 2004, 300, 65-71.	1.2	91
178	Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.. Blood, 2004, 104, 145-145.	0.6	6
179	Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.. Blood, 2004, 104, 618-618.	0.6	2
180	A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 2003, 102, 2763-2767.	0.6	262

#	ARTICLE	IF	CITATIONS
181	An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2003, 9, 5465-76.	3.2	242
182	Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2002, 36, 303-307.	0.9	18
183	A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. <i>Oncology Reports</i> , 2001, 8, 225.	1.2	1
184	Effects of Vascular Endothelial and Platelet-derived Growth Factor Receptor Inhibitors on Long-term Cultures from Normal Human Bone Marrow. <i>Growth Factors</i> , 2001, 19, 1-17.	0.5	18
185	Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. <i>Blood</i> , 2001, 98, 241-243.	0.6	131
186	Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. <i>Angiogenesis</i> , 2001, 4, 193-206.	3.7	71
187	Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. , 2000, 88, 344-351.		34
188	Author reply. <i>Cancer</i> , 2000, 89, 222-223.	2.0	1
189	In vitro differentiation of endothelial cells from AC133-positive progenitor cells. <i>Blood</i> , 2000, 95, 3106-3112.	0.6	944
190	Sensitivity of Assays Designed for the Detection of Disseminated Epithelial Tumor Cells Is Influenced by Cell Separation Methods. <i>Clinical Chemistry</i> , 2000, 46, 435-436.	1.5	16
191	Angiogenic switch and vascular stability in human Leydig cell tumours. <i>Angiogenesis</i> , 1999, 3, 231-240.	3.7	9
192	Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 621-629.	1.2	82
193	Antimycotic Therapy with Liposomal Amphotericin-B for Patients Undergoing Bone Marrow or Peripheral Blood Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 1997, 24, 491-499.	0.6	14
194	Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia. <i>Blood</i> , 1997, 89, 1870-1875.	0.6	417
195	Karyotype in multiple myeloma and plasma cell leukaemia. <i>European Journal of Cancer</i> , 1993, 29, 1269-1273.	1.3	82
196	GCSF gene is expressed but not rearranged in a patient with isochromosome 17q positive acute nonlymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1993, 68, 49-51.	1.0	7
197	A pilot study of recombinant human TNF and interferon $\gamma$ in four patients with refractory AML. <i>European Journal of Haematology</i> , 1992, 48, 115-116.	1.1	0
198	Mitoxantrone/high-dose ara-c and recombinant human gm-csf in the treatment of refractory non-hodgkin's lymphoma a pilot study. <i>Cancer</i> , 1990, 66, 423-430.	2.0	46

#	ARTICLE	IF	CITATIONS
199	Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group. <i>Cancer</i> , 1990, 66, 838-843.	2.0	13
200	Immunophenotype of Abnormal Metaphases Demonstrating Multilineage Involvement in Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 1990, 2, 201-205.	0.6	2
201	GM-CSF in busulfan overdosage. <i>European Journal of Haematology</i> , 1990, 45, 183-184.	1.1	5
202	T-cell activation defect in common variable immunodeficiency: Restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. <i>Clinical Immunology and Immunopathology</i> , 1987, 44, 206-218.	2.1	37